NBS HEALTHCARE CONFERENCE PRESENTER Piper Jaffray 24th

New Post Public Reply Private Reply Replies (0) Message Board

Nov 26, 2012 at 9:49 AM

[b]NBS >> HEALTHCARE CONFERENCE PRESENTER >> Piper Jaffray 24th Annual Healthcare Conference[/b]

2012-11-26 07:30 ET - News Release

NEW YORK, Nov. 26, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that Company management has been invited to present at the Piper Jaffray 24th Annual Healthcare Conference.

Date: Wednesday, November 28, 2012 at 9:30 AM EST
Venue: The New York Palace Hotel, New York, NY
Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation
About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Red-Eye Flights Surge, Driven By Western U.S. Routes

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Midlife ADHD in Women: New Challenges and Solutions

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Shareholder Rights in Focus: Examining Key Buyouts

Shareholder Concerns Rise Amid Corporate Buyouts The stakes are high for the shareholders of Distribution Solutions Group, Eagle Financial Services, Safety Insurance Group, and Utz Brands as their companies face potential buyouts. Let's chew over what's on the table: the sweet deals insiders might score and the legal maneuvers in play. Halper Sadeh LLC, a heavy-hitting...

Mobile Iron IV Expansions: Targeting Texas Health Needs

Out in Texas, folks facing iron deficiency have a new game-changer coming their way. Drip Gym, the same outfit making waves out in Queens and Long Island, is taking their mobile iron IV therapy clinic straight to Texan doorsteps. No more trotting off to a clinic for iron infusions with this crew rolling into Houston, Dallas, Austin, and San Antonio. What's the Big Deal?...

Albertsons Welcomes Once Upon a Coconut Nationwide

Coconut Water Takes Over Grocery Aisles You know, for all the cautious optimism I wield, this here is a move that shows real muscle in the world of coconut water—I mean, slamming into Albertsons' grocery empire is no small potatoes! Once Upon a Coconut has landed its premium hydration cans across all the banners under this giant retailer. From that good ol' familiar...

Cove Capital Secures $9.96M for Debt-Free Logistics DST

Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...

RTI's $14M Boost: A Game-Changer for Tech Innovators

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Cap Juluca: Caribbean Luxury Redefined on Maundays Bay

The Tranquil Call of Maundays Bay Find me dipping my toes in the sands of Maundays Bay come October 10, 2026, and you'll understand why this slice of Anguilla stakes its claim to being the best beach on the globe. Cap Juluca, that crown jewel of Caribbean luxury, swings open its doors once more, promising indulgence framed by turquoise waters and the soft whisper of white...

Monib Zirvi's Dermatology Excellence Honored in 2026

Trailblazer in Dermatology Recognized Again Fancy yourself a star in dermatology? Well, take notes from Dr. Monib A. Zirvi. The guy just got his due recognition from Marquis Who's Who for his sizable contributions to dermatology and research. For someone who's been at this game for over two decades, Zirvi doesn't just glide by on old merits. He's the real deal, and his...

Health Net's $2M Boost for Stanislaus Affordable Housing

Joining the Fight Against California’s Housing Crisis Well, I'll be the first to say it's a breath of fresh air when a healthcare beast like Health Net starts investing in something as critical as affordable housing. This is no drop in the bucket—two million dollars is quite the commitment to fix some of the mess that’s been brewing in Stanislaus County, California....